Written By | Health News Agencies
Inovio's Voceryq, cleared on Friday for a rare HPV-driven airway disease that traps patients in a cycle of repeat surgeries, is the first medicine of its kind in the US.
Search
HEALTH
Imagine having surgery to scrape growths out of your windpipe. Then, months later, having it again. And again. Imagine that every one of those operations puts your voice, and your breathing, at risk.
That is life for adults with recurrent respiratory papillomatosis (RRP), a rare condition in which wart-like growths caused by the human papillomavirus (HPV) keep returning in the airway. On Friday 30 October 2026, the US Food and Drug Administration approved a new kind of medicine that aims to break that cycle: Voceryq, from Inovio Pharmaceuticals. The agency called it the first plasmid DNA-based immunotherapy ever approved in the United States.
The stock market reacted instantly. Inovio's shares jumped 257 percent in extended trading after the decision. Its competitor Precigen saw its stock crater 27 percent in after-hours trading.
A Disease That Keeps Coming Back
RRP is caused by HPV types 6 and 11. The growths, called papillomas, form in the larynx and airway. Surgeons can remove them, but the virus remains, and the growths regrow. Some patients endure operation after operation, year after year.
The numbers in Inovio's own trial tell the story. Patients were only eligible if they had needed two or more surgeries in the previous 12 months, and the main efficacy group of 26 patients had at least three baseline surgeries, with a median of 4.5 and a range of three to eight. In other words, the typical person in the trial was having an operation roughly every two to three months.
Dr. Simon Best of Johns Hopkins, an investigator in the study, has pointed out the risk hiding in each procedure: "every surgery carries the risk of laryngeal injury."
Karim Mikhail, director of the FDA's Center for Biologics Evaluation and Research, described the burden in the agency's announcement: adults living with RRP, he said, "often face an exhausting and relentless cycle of repeated surgeries."
So What Is Voceryq, Exactly?
Voceryq, known during development as INO-3107, is not a pill or a conventional vaccine. It is built from two pieces of DNA called plasmids. One carries the genetic instructions for HPV-6 and HPV-11 antigens, the parts of the virus the immune system can learn to recognise. The other encodes interleukin-12, a signalling molecule that helps rev up the immune response.
The idea is to teach the patient's own immune system to find and attack cells infected with the two HPV types, so the growths stop returning.
Delivery is high-tech. The plasmids are injected into muscle and then given a brief electrical pulse using a device called CELLECTRA 5PSP, a process known as electroporation, which helps cells take up the DNA. The regimen runs over nine weeks and follows standard surgery to remove visible growths. The generic names given for the product are doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd.
The FDA granted the product both Breakthrough Therapy and Orphan Drug designations, signals that the agency saw promise in a disease with few options.
What the Trial Showed
The approval rests on an open-label, multicentre phase 1/2 study, called RRP-001, in 32 adults whose disease was linked to HPV-6, HPV-11 or both.
In the efficacy group of 26 patients, seven (27 percent) had what is called a complete response, meaning they needed no surgical removal of papillomas over the following 12 months. The 95 percent confidence interval stretched from 12 to 48 percent, which tells you the estimate is imprecise because the study was small. The company argues that such a result is not expected in the natural history of untreated disease. But there was no control group and no P value reported, so caution is warranted.
That caution is exactly why this was an accelerated approval. The FDA treats the trial result as an intermediate clinical endpoint that is reasonably likely to predict real clinical benefit, not as final proof. Inovio must now run confirmatory studies. The company is due to submit a draft protocol to the FDA by the end of 2026, with the final design expected to be agreed by mid-2027.
Safety: What Patients Should Know
On the safety front, the early signals were encouraging. The most common side effects, seen in more than five percent of patients, were injection-site reactions, headache, fatigue, high blood pressure, nausea and dizziness. Most treatment-related reactions were mild to moderate and short-lived. There were no grade 4 or grade 5 events, and all 32 patients completed the study.
The electroporation step does come with its own cautions. It can cause muscle contractions, brief bleeding and fainting-type reactions, so injection sites should be monitored for at least 30 minutes afterwards. It should be avoided on the same side of the body as an implanted defibrillator or pacemaker, metal implants, or skin abnormalities at the injection site.
A Crowded Little Market
Voceryq is not the first medicine for RRP. Precigen's Papzimeos received US approval last year as the first therapy for the condition in adults. It aims at the same two HPV types, but works differently, using a modified virus to trigger the immune response, whereas Voceryq uses DNA.
That head-to-head context explains the whiplash on Wall Street. Inovio, whose first-ever approved product is Voceryq, saw its shares soar. Precigen's stock fell about 27 percent in extended trading as investors weighed the new competitor.
Inovio chief executive Jacqueline Shea told Reuters that physicians mainly want therapies that reduce the need for surgery. That is the yardstick on which both products will ultimately be judged. The price of Voceryq has not been disclosed. The company expects the product to be available to order and ship in about 60 days, with a full commercial launch planned for the first quarter of 2027.
Why It Matters Beyond One Rare Disease
RRP is rare, but this approval carries weight beyond its patient numbers. DNA medicines have long been promised as a flexible platform: swap in a different genetic sequence and, in theory, you can aim the same technology at a new target. A first US approval for a plasmid DNA immunotherapy opens a regulatory path that others can follow, whether against other viruses or against cancers.
It also shows the FDA's willingness to use accelerated approval for rare diseases where waiting for large, long trials may be impractical. The trade-off is uncertainty. Patients and doctors will be making decisions with limited data, trusting that confirmatory trials will back up the early promise.
Importantly, the finding is also a reminder of what HPV can do beyond the cervical and other cancers most people associate it with. HPV types 6 and 11 are not the cancer-causing types; they cause these stubborn growths, and in the airway the growths can be dangerous because of where they sit.
The Road Ahead: Key Dates
For patients and investors alike, the calendar now matters. The FDA's decision landed on the product's PDUFA goal date, the deadline by which the agency had promised an answer, so there was no delay or surprise extension. From here, Inovio says Voceryq should be orderable within roughly 60 days of approval, putting the first orders around the end of the year. Full field deployment, meaning the wider rollout of the product and the electroporation device to treatment centres, is planned for the first quarter of 2027.
Behind the scenes, the regulatory clock is also ticking. A draft confirmatory protocol is due at the FDA by the end of 2026, and final alignment on the study is expected by mid-2027. Under the rules of accelerated approval, failing to deliver convincing confirmatory evidence can put an approval at risk, so the next chapter of this story will be written in clinics and trial sites rather than on trading screens.
Doctors will also need to learn how to use the electroporation device safely and to schedule the nine-week regimen around each patient's surgeries. That practical work, rather than the headlines, will determine how quickly patients actually benefit.
What the Critics Say
Not everyone is popping champagne. The trial was small, open-label and uncontrolled. A 27 percent complete response rate means that most patients in the efficacy group still needed at least one surgery in the 12 months. The confidence interval runs as low as 12 percent. Without a comparison group, it is impossible to say with certainty how much of the benefit came from the drug, the surgery that preceded it, or the natural ups and downs of the disease. These are fair questions, and they are precisely the questions the FDA expects the confirmatory trial to answer.
What This Means For You
If you or a loved one has RRP, talk to a specialist, typically an ear, nose and throat surgeon with experience in the condition, about whether Voceryq or the other approved option is suitable. The approval is for adults, and the drug is expected to be orderable in around 60 days, so availability in clinics will take a little while.
If you have no connection to RRP, the practical lesson is about HPV in general. Vaccination against HPV is a well-established way to guard against the virus's many harmful effects. Ask your doctor about it.
And if you are interested in medical innovation, watch this space. The first DNA-based immunotherapy has crossed the finish line, and what comes after it may matter much more than the disease it first treats.
The Bottom Line
Voceryq will not cure everyone, and the evidence behind it is still early. But for a group of patients whose lives have been dominated by repeated surgery, any new option that might cut the number of operations is welcome. For medicine more broadly, a DNA immunotherapy has now been cleared by the FDA for the first time. The confirmatory trial results, due in the years ahead, will show whether this was a landmark or a false dawn.
